article review on tocilizumab production


Tocilizumab (Actemra) is a humanized monoclonal antibody that targets the interleukin-6 (IL-6) receptor, which is involved in the inflammatory response. It is used to treat rheumatoid arthritis, systemic juvenile idiopathic arthritis and other inflammatory conditions. It is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells.

One research article "Development of an efficient and scalable fed-batch culture process for the production of tocilizumab in Chinese hamster ovary cells" by Li et al. (2019) aimed to optimize the production of tocilizumab using a fed-batch cultivation system in CHO cells. The study aimed to improve the yield and quality of the protein, and to develop a process that can be easily scaled up for industrial production.

The results of the study showed that the yield of tocilizumab was significantly improved by optimizing the culture conditions, such as the temperature, pH, and dissolved oxygen, as well as by using a specific expression vector and a specific promoter. The study also found that the productivity of the cells was highest during the late exponential phase of the culture, and that the quality of the protein was similar to that of the clinically used product, with a high degree of purity, stability, and bioactivity.

In addition, the study showed that the fed-batch process can be easily scaled up for industrial production, and the production process can be adapted to different bioreactors.

Comments

Popular posts from this blog

MOA OF AMINOGLYCOSIDE ANTIBIOTICS

article review on adalimumab production

Why 70% Isopropyl Alcohol (IPA) is used as Disinfectant in Pharmaceuticals?